Drugs Information:
Ropinirole
Basic Information
|
||
ID | DDInter1619 | |
Drug Type | small molecule | |
Molecular Formula | C16H24N2O | |
Molecular Weight | 260.375 | |
CAS Number | 91374-21-9 | |
Description | Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], [A174547]. It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole [A35711]. | |
ATC Classification | N04BC04 | |
IUPAC Name | 4-[2-(dipropylamino)ethyl]-2,3-dihydro-1H-indol-2-one | |
InChI | UHSKFQJFRQCDBE-UHFFFAOYSA-N | |
Canonical SMILES | CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1 | |
Useful Links | DrugBank ChEBI PubChem Substance KEGG Compound KEGG Drug ChemSpider BindingDB PharmGKB Therapeutic Targets Database Wikipedia ChEMBL ZINC |
Interactions with
Ropinirole
Filter:
Severity level | ID | Name | Mechanism | Detail |
---|
Interactions with diseases
Filter:
Severity level | Disease name | Text | References |
---|
Interactions with foods
Filter:
Severity level | Food name | Description | Management | Mechanism | References |
---|
Interactions with compound preparation
Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
---|